Request Demo
Last update 05 Sep 2025
Dydrogesterone
Last update 05 Sep 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms (9β,10α)-pregna-4,6-diene-3,20-dione, 10α-Isopregnenone, 6-Dehydro-retro-progesterone + [19] |
Target |
Action agonists |
Mechanism PR agonists(Progesterone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United Kingdom (01 Jan 1961), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS Registry152-62-5 |
Related
163
Clinical Trials associated with DydrogesteroneChiCTR2500105270
Comparison of the effect of combination of alprosterone and dydrogesterone on luteal support after fresh cycle transplantation
CTR20251751
地屈孕酮片在中国健康受试者中单剂量、两制剂、四周期、两序列、随机、开放、完全重复交叉的空腹和餐后状态下生物等效性试验
[Translation] A single-dose, two-formulation, four-cycle, two-sequence, randomized, open-label, completely repeated crossover bioequivalence study of dydrogesterone tablets in Chinese healthy subjects under fasting and fed conditions
CTR20251220
地屈孕酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
[Translation] A human bioequivalence clinical trial of dydrogesterone tablets in Chinese healthy subjects after single administration under fasting and fed conditions
100 Clinical Results associated with Dydrogesterone
Login to view more data
100 Translational Medicine associated with Dydrogesterone
Login to view more data
100 Patents (Medical) associated with Dydrogesterone
Login to view more data
991
Literatures (Medical) associated with Dydrogesterone01 Sep 2025JOURNAL OF ETHNOPHARMACOLOGY
Exploring the inhibitory effects of Guben Antai Decoction on oxidative stress damage and ferroptosis via the Nrf2/HO-1 pathway: A mechanistic study on improving Recurrent Spontaneous Abortion
Article
Author: Li, Yongwei ; Wang, Chunxia ; Du, Xin ; Li, Xuebing ; Han, Mingyue ; Zhang, Xin ; Lu, Ruici ; Yang, Bingyao ; Su, Zhuoxuan
ETHNOPHARMACOLOGICAL RELEVANCE:
Guben Antai Decoction (GBAT) is a traditional Chinese medicine formula that significantly increases embryo implantation rates and reduces early pregnancy loss in patients with recurrent spontaneous abortion (RSA).
AIM OF THE STUDY:
This study aims to explore the influence and possible mechanism of GBAT in improving recurrent spontaneous abortion.
MATERIALS AND METHODS:
In vivo, normal pregnancy and RSA models were established using CBA/J female × BALB/c male and CBA/J female × DBA/2 male mouse pairings, respectively. GBAT (18.05 g/kg/d) or dydrogesterone (DYD; 3.03 mg/kg/d) was intragastrically administered to pregnant mice in the RSA model from gestational day 1. An oxidative stress model was established in vitro by treating human trophoblast HTR-8/SVneo cells with H2O2. Placental villi damage was assessed using hematoxylin and eosin staining, and mitochondrial morphology was examined using transmission electron microscopy. The expression of GPX4, ACSL4, SLC7A11, Nrf2, and HO-1 were measured using RT-qPCR, western blotting, and immunohistochemistry. Lipid peroxidation markers ROS, GSH, GPx, MDA, and Fe2+ were quantified using commercial kits.
RESULTS:
In mice with RSA, ferroptosis occurred in the placental villous tissue. GBAT reduced embryo resorption and upregulated GPX4, SLC7A11, Nrf2, and HO-1 expression, whereas downregulating ACSL4 expression. In vitro, H2O2-induced ferroptosis decreased trophoblast viability and caused ROS accumulation and lipid peroxidation. GBAT attenuated these effects by activating Nrf2. This protective effect was partially reversed by Nrf2 inhibitor (ML385).
CONCLUSION:
This study is the first to demonstrate that GBAT mitigates ferroptosis in trophoblasts by activating the Nrf2/HO-1 pathway, providing new mechanistic insights into its potential for treating RSA.
14 Aug 2025Journal of Ovarian Research
Comparison of oral dydrogesterone and vaginal progesterone for luteal phase support in natural and modified natural cycle frozen embryo transfers.
Article
Author: Li, Lin ; Jiang, Lin-Lin ; Li, Yu ; Pan, Ping ; Qiu, Qi ; Huang, Jia ; Xie, Yan-Xin
BACKGROUND:
This study evaluates the effectiveness of oral dydrogesterone (DYD) for luteal phase support on pregnancy outcomes in patients undergoing frozen embryo transfer with natural cycle protocols (NC-FET), compared with micronized vaginal progesterone (MVP) and combined therapy.
METHODS:
A retrospective study analyzed 2,035 NC-FET cycles, including both natural and modified natural cycles, conducted between January 2019 and August 2022. A total of 2,035 NC-FET cycles were analyzed. Participants were categorized into three groups based on luteal phase support regimens: Group A (699 cycles) received oral DYD, Group B (433 cycles) received MVP, and Group C (903 cycles) received combination therapy. The live birth rates and neonatal outcomes were compared among the groups.
RESULTS:
The live birth rates were comparable across the groups (43.8%, 39.0%, and 42.1%; P > 0.05). No significant variations were found in clinical pregnancy rate, spontaneous miscarriage rate, ectopic pregnancy rate, premature birth rate, and newborn birth weights. Embryo implantation rates in Groups A and C were significantly higher than in Group B (44.1% and 42.9% vs. 37.8%; P = 0.029). Multi-factor regression analysis identified several independent variables influencing the live birth rate, but luteal support regimens did not significantly impact live birth rates (P > 0.05).
CONCLUSION:
In NC-FET cycles, oral DYD demonstrates clinical efficacy comparable to MVP and combined medication. As a monotherapy, oral DYD expands therapeutic options, offering a convenient and effective choice to improve adherence and achieve similar pregnancy outcomes. This finding is significant for guiding clinical practices towards optimal treatment strategies that prioritize patient compliance and satisfaction.
01 Aug 2025European Journal of Obstetrics & Gynecology and Reproductive Biology
Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety
Review
Author: Saraiva, Cainã Araújo ; Oliveira Amador, Wellgner Fernandes ; Queiroz, Ivo ; Pinilla Alarcón, Juan Alejandro ; Roberto De Sa, Joao ; Iqbal, Asad ; de Souza Gaio, Giovana ; Ruelas, Mariano Gallo
OBJECTIVES:
To evaluate the efficacy and safety of pharmacological treatments for vasomotor symptoms (VMS) in postmenopausal women.
METHODS:
A systematic search was conducted in PubMed, Embase, and the Cochrane Library through January 2025. Eligible studies were Phase 3 or 4 randomized controlled trials (RCTs) assessing pharmacological treatments for moderate to severe VMS with ≥ 12 weeks of follow-up. A Bayesian random-effects network meta-analysis estimated mean differences (MDs) and risk ratios (RRs) with 95 % credible intervals (CrI). Treatments were ranked using surface under the cumulative ranking (SUCRA). Risk of bias was assessed using Cochrane's tool.
RESULTS:
Forty-one RCTs (n = 14,743; mean age 53.4 years) were included. Synthetic conjugated estrogens (SCE) 1.25 mg showed the greatest reduction in VMS frequency (MD -5.69; 95 % CrI -7.93 to -3.38), while drospirenone 0.5 mg + estradiol 0.5 mg was most effective for severity (MD -1.06; 95 % CrI -1.39 to -0.72). Most treatments had safety profiles similar to placebo, though estradiol 0.5 mg + dydrogesterone 2.5 mg was linked to more adverse events (RR 1.56; 95 % CrI 1.16 to 2.24). No significant differences in serious adverse events were found. SUCRA rankings highlighted SCE and transdermal estradiol gel as most effective for frequency, while drospirenone + estradiol led for severity. Fezolinetant and elinzanetant showed moderate efficacy. Of the studies, 22 had low risk of bias, and 19 had some concerns.
CONCLUSIONS:
Conjugated estrogens and drospirenone with estradiol are the most effective options for reducing VMS frequency and severity, and Fezolinetant and Elinzanetant showed moderate efficacy, with overall similar safety across treatments.
14
News (Medical) associated with Dydrogesterone
100 Deals associated with Dydrogesterone
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01217 | Dydrogesterone |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Uterine Hemorrhage | China | 31 Dec 2002 | |
| Abortion, Habitual | Japan | 31 Oct 1964 | |
| Abortion, Threatened | Japan | 31 Oct 1964 | |
| Amenorrhea | Japan | 31 Oct 1964 | |
| Dysmenorrhea | Japan | 31 Oct 1964 | |
| Infertility | Japan | 31 Oct 1964 | |
| Metrorrhagia | Japan | 31 Oct 1964 | |
| Endometriosis | United Kingdom | 01 Jan 1961 | |
| Menstruation Disturbances | United Kingdom | 01 Jan 1961 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Infertility, Female | Phase 3 | Austria | 01 Aug 2013 | |
| Infertility, Female | Phase 3 | Belgium | 01 Aug 2013 | |
| Infertility, Female | Phase 3 | Finland | 01 Aug 2013 | |
| Infertility, Female | Phase 3 | Germany | 01 Aug 2013 | |
| Infertility, Female | Phase 3 | Israel | 01 Aug 2013 | |
| Infertility, Female | Phase 3 | Russia | 01 Aug 2013 | |
| Infertility, Female | Phase 3 | Spain | 01 Aug 2013 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 172 | iyixwvpbqz = kkkefshrhq hhxjehergu (nlfmhgybyi, wljlvzqfzj - pwdnslthtp) View more | - | 12 Mar 2024 | |||
Phase 3 | 90 | (the Progestin Primed Double Stimulation Group) | dmcrdgljrv(aigukfatwl) = drrhcozfkt fometkyhfw (bjrnhdnetr, wllsypipqx - dhlhuzsasy) View more | - | 17 Feb 2022 | ||
(the Flexible GnRh Antagonist) | zabtedujwb(garjznpucr) = aczebqngmd xquxvvwuty (xfbwhqsuyz, osetsyqziy - ygvbxakeiu) View more | ||||||
Phase 4 | 48 | Oral dydrogesterone 10mg | uxenrqnpyj(kdxweqfvmv) = cermdjwxsw pvrnqkbzee (syaxureyzv ) | Negative | 28 Jan 2021 | ||
Placebo | uxenrqnpyj(kdxweqfvmv) = aldxnzovzd pvrnqkbzee (syaxureyzv ) | ||||||
Phase 3 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | arperdycds = wyggdpdmsh nrskpgtjmz (hlqaztmugw, tabbbrdtwz - lpnujxfcpv) View more | - | 01 Oct 2019 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | arperdycds = psbijpglfk nrskpgtjmz (hlqaztmugw, aivusmegmq - mkkfiidoea) View more | ||||||
Phase 3 | 1,034 | wtibptrsuh(brxfjeswfd) = ofvuleghny kwfsmllggs (fcgjdwirqg ) View more | Positive | 10 Oct 2018 | |||
8% MVP gel 90 mg | wtibptrsuh(brxfjeswfd) = eiiteensqm kwfsmllggs (fcgjdwirqg ) View more | ||||||
Phase 3 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | qryjeskaha = cogkswbhbl ycwoouyubr (vnqzlozxow, poicoaryti - lzwzyffucf) View more | - | 02 Jan 2018 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | qryjeskaha = ipsznpvzgx ycwoouyubr (vnqzlozxow, utqsnmhthx - fkmynnqnsv) View more | ||||||
Phase 3 | - | 1,031 | Oral dydrogesterone 30 mg daily | kyfsgqufbg(ppxupijrvk) = hgeswmbyma xnnrqzidtd (ywkehzomym ) View more | Positive | 01 May 2017 | |
Micronized vaginal progesterone 600 mg daily | kyfsgqufbg(ppxupijrvk) = xkkfeajbxa xnnrqzidtd (ywkehzomym ) View more | ||||||
Phase 4 | Obstetric Labor, Premature Adjuvant | 48 | Oral dydrogesterone (20mg daily) | ukyclpwbdg(xensrmdpch) = dvtegeyrpr rzoulfumgo (lklsadmjry ) View more | Negative | 09 Feb 2016 | |
Oral placebo | ukyclpwbdg(xensrmdpch) = qwunvzdrvb rzoulfumgo (lklsadmjry ) View more | ||||||
Not Applicable | - | 853 | Crinone 8% vaginal progesterone gel | dhkwkixytp(fktbnnoaac) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group gtpqcscedp (xyerfhrysw ) View more | - | 01 Mar 2015 | |
Oral dydrogesterone Duphaston | |||||||
Phase 4 | 191 | ecszdzrxdc(zrabhxbfxu) = bekavsvnhh dedfpbseqt (rvfdtbyvtj ) | Positive | 01 Dec 2009 | |||
(Conservative management) | ecszdzrxdc(zrabhxbfxu) = nduqjvnohf dedfpbseqt (rvfdtbyvtj ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free